Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Arthritis & Rheumatism

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Urology

Show all topics

DOI

10.1002/art.23417